ROCKET PHARMACEUTICALS, INC.
Business
Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company developing genetic therapies for rare and fatal diseases using AAV and lentiviral vector platforms. The company is advancing a portfolio of gene therapy candidates targeting inherited cardiomyopathies (Danon disease, plakophilin-2 arrhythmogenic cardiomyopathy, BAG3 dilated cardiomyopathy) and rare hematologic disorders (leukocyte adhesion deficiency, Fanconi anemia, pyruvate kinase deficiency). Rocket operates a cGMP manufacturing facility in Cranbury, New Jersey, and is pursuing regulatory approvals in the U.S. and Europe.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 142 | 171 | 186 | 166 | 125 | |
| General and administrative | 87 | 102 | 73 | 59 | 42 | |
| Restructuring | 3 | 0 | — | — | — | |
| Total operating expenses | 232 | 273 | 260 | 224 | 167 | |
| Loss from operations | −232 | −273 | −260 | −224 | −167 | |
| Interest expense | −2 | −2 | −2 | −2 | −3 | |
| Interest and other income, net | 3 | 8 | 5 | 4 | 3 | |
| Accretion of discount on investments, net | 7 | 8 | 11 | −47,000 | −3 | |
| Net loss | −223 | −259 | −246 | −222 | −169 | |
| Net loss per share - basic (in dollars per share) | −2.01 | −2.73 | −2.92 | −3.26 | −2.67 | |
| Net loss per share - diluted (in dollars per share) | −2.01 | −2.73 | −2.92 | −3.26 | −2.67 | |
| Weighted-average common shares outstanding - basic (in shares) | 111 | 95 | 84 | 68 | 63 | |
| Weighted-average common shares outstanding - diluted (in shares) | 111 | 95 | 84 | 68 | 63 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-03-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 78 | 164 | 56 | — | 141 | |
| Investments | 111 | 209 | 317 | — | 216 | |
| Prepaid expenses and other current assets | 4 | 6 | 5 | — | 8 | |
| Total current assets | 193 | 378 | 378 | — | 364 | |
| Property and equipment, net | 28 | 37 | 39 | — | 29 | |
| Goodwill | 39 | 39 | 39 | — | 39 | |
| Intangible assets | 25 | 25 | 25 | — | 26 | |
| Restricted cash | 1 | 1 | 1 | — | 1 | |
| Deposits | 482,000 | 529,000 | 533,000 | — | 608,000 | |
| Operating lease right-of-use assets, net | 3 | 4 | 4 | 200,000 | 2 | |
| Finance lease right-of-use asset, net | 40 | 42 | 45 | — | 47 | |
| Total assets | 330 | 528 | 566 | — | 552 | |
| Accounts payable and accrued expenses | 27 | 38 | 46 | — | 37 | |
| Operating lease liabilities, current | 1 | 1 | 925,000 | — | 773,000 | |
| Finance lease liability, current | 2 | 2 | 2 | — | 2 | |
| Total current liabilities | 30 | 41 | 49 | — | 39 | |
| Operating lease liabilities, non-current | 3 | 3 | 3 | 200,000 | 1 | |
| Finance lease liability, non-current | 19 | 19 | 19 | — | 19 | |
| Other liabilities | 1 | 1 | 3 | — | 3 | |
| Total liabilities | 53 | 64 | 74 | — | 62 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Common stock, $0.01 par value, 180,000,000 shares authorized; 108,319,783 and 106,453,818 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | 1 | 1 | 903,000 | — | 791,000 | |
| Additional paid-in capital | 1,717 | 1,680 | 1,451 | — | 1,203 | |
| Accumulated other comprehensive (loss) income | −31,000 | 66,000 | 319,000 | — | −357,000 | |
| Accumulated deficit | −1,440 | −1,218 | −959 | — | −714 | |
| Total stockholders' equity | 277 | 463 | 493 | — | 490 | |
| Total liabilities and stockholders' equity | 330 | 528 | 566 | — | 552 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization of property and equipment | 9 | 7 | 5 | 4 | 3 | |
| Amortization of finance lease right of use asset | 2 | 2 | 2 | 2 | 2 | |
| Impairment of operating lease right-of-use asset | 262,000 | 0 | — | — | — | |
| Stock-based compensation | 37 | 44 | 39 | 31 | 29 | |
| Accretion of discount on investments, net | −7 | −8 | −10 | 134,000 | 3 | |
| Change in fair value of warrant liabilities | 0 | −2 | −364,000 | — | — | |
| Prepaid expenses and other assets | 2 | −661,000 | 3 | −4 | 1 | |
| Accounts payable and accrued expenses | −10 | 6 | 10 | 10 | −5 | |
| Operating lease liabilities and right of use assets, net | 45,000 | 89,000 | 137,000 | −120,000 | −11,000 | |
| Finance lease liability | 35,000 | 95,000 | 139,000 | 172,000 | 201,000 | |
| Other liabilities | −81,000 | 81,000 | 705,000 | −57,000 | −56,000 | |
| Net cash used in operating activities | −190 | −210 | −195 | −178 | −121 | |
| Purchases of investments | −277 | −246 | −391 | −376 | −246 | |
| Proceeds from maturities of investments | 381 | 383 | 309 | 273 | 272 | |
| Purchases of property and equipment | −440,000 | −6 | −16 | −8 | −8 | |
| Net cash provided by investing activities | 104 | 132 | −98 | −69 | 19 | |
| Issuance of common stock pursuant to exercise of stock options | 0 | 3 | 2 | 631,000 | 11 | |
| Return of related party short-swing profits | 215,000 | 0 | — | — | — | |
| Repurchase of restricted stock units to satisfy tax withholding | −67,000 | 0 | — | — | — | |
| Net cash provided by financing activities | 148,000 | 186 | 208 | 155 | 38 | |
| Net change in cash, cash equivalents and restricted cash | −86 | 108 | −85 | −92 | −65 | |
| Accrued purchases of property and equipment, ending balance | 0 | 185,000 | 1 | 2 | 728,000 | |
| Receivables from sale of property and equipment, ending balance | 0 | 135,000 | 0 | 0 | — | |
| Operating lease liabilities | 0 | 1 | 3 | 0 | 0 | |
| Operating lease right of use assets | 0 | 1 | 3 | 0 | — | |
| Net unrealized loss on investments | −100,000 | −300,000 | 700,000 | −200,000 | −100,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ROCKET PHARMACEUTICALS, INC.'s CIK number?
ROCKET PHARMACEUTICALS, INC.'s SEC CIK number is 0001281895 (1281895). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ROCKET PHARMACEUTICALS, INC.'s SEC filings?
All of ROCKET PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ROCKET PHARMACEUTICALS, INC. last report earnings?
ROCKET PHARMACEUTICALS, INC. (RCKT) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001140361-26-019573). This is ROCKET PHARMACEUTICALS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ROCKET PHARMACEUTICALS, INC.'s most recent earnings 8-K?
ROCKET PHARMACEUTICALS, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001140361-26-019573. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ROCKET PHARMACEUTICALS, INC.'s latest earnings 8-K →
Look up any company's CIK number →